Satellos expects to begin first-in-human clinical trials
mid-year for SAT-3247, an oral small molecule drug candidate in
development as a novel regenerative medicine approach to treating
DMD
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX:
MSCL, OTCQB: MSCLF), a public biotech company developing new small
molecule therapeutic approaches to improve the treatment of muscle
diseases and disorders, announced today the formation of a Clinical
Advisory Board comprised of distinguished clinical research leaders
and experts in drug development in genetic muscle disorders,
including Duchenne muscular dystrophy (DMD or Duchenne).
“The formation of this Clinical Advisory Board marks a major
development step for Satellos as we continue our evolution in
becoming a clinical stage drug development company,” said Frank
Gleeson, Co-founder and CEO of Satellos. “We are proud and excited
to bring together leading clinicians and scientists from across the
world who are dedicated to, and have decades of experience in, the
clinical development of novel therapeutics for degenerative muscle
disorders. We believe this will help support Satellos in advancing
our lead drug candidate, SAT-3247, as we work to optimize its
potential to transform the treatment of Duchenne and serious muscle
diseases.”
The members of the Clinical Advisory Board (CAB) are as
follows:
Jordan Dubow, M.D., Chair of the CAB and Chief Medical
Advisor, Satellos, has extensive experience in the
biopharmaceutical industry, leading all aspects of clinical and
regulatory development in Chief Medical Officer (CMO) capacities
for both public and private companies, playing pivotal roles on 16
new drug applications (NDAs), including in DMD.
Ronald Cohn, M.D., Ph.D., President and CEO, Hospital for
Sick Children, is an outstanding clinician scientist devoted to
discovering new diagnostic and treatment options for pediatric
disease and an accomplished scientist dedicated to muscular
dystrophies. Research in his laboratory focuses on utilizing genome
editing technologies like CRISPR for the development of therapeutic
approaches for neurogenetic disorders.
Richard Finkel, M.D., Director, Center for Experimental
Neurotherapeutics, St. Jude Children's Research Hospital, is an
experienced translational researcher and international leader in
organizing key clinical trials for neuromuscular diseases,
including DMD and spinal muscular atrophy, for which he played a
vital role in developing the first successful therapy.
Nicholas Johnson, M.D., MSCI, FAAN, Director of the
Center for Inherited Myology Research, George Bliley Research
Chair, and Professor and Vice Chair of Research in Neurology,
conducts therapeutic trials in inherited nerve and muscle disorders
and also dedicates significant time to laboratory research as part
of a team at VCU Health working to advance the treatment of genetic
muscle disorders, with a special emphasis on muscular
dystrophies.
Hanns Lochmüller, M.D., Ph.D., Senior Scientist,
Children’s Hospital of Eastern Ontario Research Institute, is a
neurologist and clinical academic focused on clinical research and
care of patients with rare genetic neuromuscular disorders. His
research includes molecular therapies of neuromuscular disorders
and molecular pathogenesis of muscle and neuromuscular junction
disorders.
Francesco Muntoni, M.D., Director, Dubowitz Neuromuscular
Centre, Great Ormond Street UCL Institute of Child Health, is
focused on advancing novel therapeutics in translational and
clinical research for pediatric neuromuscular disorders, especially
Duchenne muscular dystrophy. His efforts in the last 20 years led
to two FDA-approved therapies for DMD (eteplirsen and
golodirsen).
Perry Shieh, M.D., Ph.D., FAAN, Professor of Neurology,
UCLA David Geffen School of Medicine. Dr. Shieh’s principal
clinical interests include Duchenne muscular dystrophy (DMD),
facioscapulohumeral muscular dystrophy (FSHD), and myotonic
dystrophy. He has served as an investigator in numerous clinical
trials for neuromuscular conditions.
For full bios, visit www.satellos.com/about.
About SAT-3247 SAT-3247 is an oral small molecule drug
designed to target the root cause of muscle loss in degenerative
diseases initially in Duchenne. SAT-3247 presents a novel mechanism
of action to restore impaired muscle regeneration caused by the
absence of functional dystrophin.
About Duchenne Muscular Dystrophy Duchenne muscular
dystrophy is an inherited disease caused by mutations in the
dystrophin gene that no longer allow the dystrophin protein to
function properly. Consequently, as discovered by Satellos, muscle
repair and regeneration is impaired. Satellos designed SAT-3247 to
restore the process of muscle repair and regeneration by regulating
a dystrophin-independent pathway with the goal of increasing muscle
function. SAT-3247 is intended to work as a standalone therapeutic
without regard to a patient’s genetic mutation or ambulatory
status. Our approach has the potential to complement approaches
designed to restore dystrophin production.
About Satellos Bioscience Inc. Satellos is a publicly
traded biotechnology company dedicated to developing life-improving
medicines to treat degenerative muscle diseases. Satellos has
incorporated breakthrough research in muscle stem cell polarity
into a proprietary discovery platform, called MyoReGenX™, to
identify degenerative muscle diseases where deficits in this
process affect muscle regeneration and are amenable to therapeutic
intervention. With this platform, Satellos is building a pipeline
of novel therapeutics to correct muscle stem cell polarity and
promote the body’s innate muscle repair and regeneration process.
The Company’s lead program is an oral, small molecule drug
candidate in development as a potential disease-modifying treatment
for Duchenne muscular dystrophy. Satellos is headquartered in
Toronto, Ontario. For more information, visit www.satellos.com.
Notice on Forward-Looking Statements This press release
includes forward-looking information or forward-looking statements
within the meaning of applicable securities laws regarding Satellos
and its business, which may include, but are not limited to,
statements regarding the anticipated benefits to patients from a
small molecule treatment for Duchenne; the advancement of our lead
drug candidate into clinical trials; our belief that our Clinical
Advisory Board will help support Satellos in advancing our lead
drug candidate, the pharmacodynamic properties and
mechanism-of-action of our lead drug candidate; the potential of
our approach in other degenerative muscle diseases or in muscle
injury or trauma; the general benefits of modulating stem cell
polarity by administering small molecule drugs; its/their
prospective impact on Duchenne patients, patients with other
degenerative muscle disease or muscle injury or trauma, and on
muscle regeneration generally; the utility of regenerating muscle
by modulating polarity; adoption of Satellos’ approach by the
medical community; and Satellos’ technologies and drug development
plans. All statements that are, or information which is, not
historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, occurrences or developments, are
“forward-looking information or statements.” Often but not always,
forward-looking information or statements can be identified by the
use of words such as “shall”, “intends”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”,
“prospective” , “assert” or any variations (including negative or
plural variations) of such words and phrases, or state that certain
actions, events or results “may”, “might”, “can”, “could”, “would”
or “will” be taken, occur, lead to, result in, or, be achieved.
Such statements are based on the current expectations and views of
future events of the management of the Company. They are based on
assumptions and subject to risks and uncertainties. Although
management believes that the assumptions underlying these
statements are reasonable, they may prove to be incorrect. The
forward-looking events and circumstances discussed in this release,
may not occur and could differ materially as a result of known and
unknown risk factors and uncertainties affecting the Company,
including, without limitation, risks relating to the pharmaceutical
and bioscience industry (including the risks associated with
preclinical and clinical trials and regulatory approvals), and the
research and development of therapeutics, the results of
preclinical and clinical trials, general market conditions and
equity markets, economic factors and management’s ability to manage
and to operate the business of the Company generally, including
inflation and the costs of operating a biopharma business, and
those risks listed in the “Risk Factors” section of Satellos’
Annual Information Form dated March 26, 2024 (which is located on
Satellos’ profile at www.sedarplus.ca). Although Satellos has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward- looking statement can be guaranteed.
Except as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and
Satellos does not undertake any obligation to publicly update or
revise any forward-looking statement, whether resulting from new
information, future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240528812819/en/
Investors: Liz Williams, ir@satellos.com Business Development:
Ryan Mitchell, Ph.D., bd@satellos.com Media: Jessica Yingling,
Ph.D., jessica@litldog.com, +1.858.344.8091
Satellos Bioscience (TSX:MSCL)
過去 株価チャート
から 12 2024 まで 1 2025
Satellos Bioscience (TSX:MSCL)
過去 株価チャート
から 1 2024 まで 1 2025
